As the volume of global post-marketing adverse event (AE) reports continues to rise at rate of 15% per year, it has become difficult for pharmacovigilance teams to handle an increased work-load with fixed resources and tight budgets.
Unsurprisingly, automation has become a widely discussed topic in the industry, with many organizations actively pursuing methods of streamlining case processing through automation technologies.
To prove the potential that automation has in transforming pharmacovigilance, ArisGlobal conducted a time study across five key use cases featuring its all-new LifeSphere MultiVigilance safety system.
The results from the time study were clear, and show that automation can lead to significant efficiency gains, while also providing helpful measurement benchmarks to plot continuous improvement over time.
Download the whitepaper to learn more.